United Therapeutics Corp $ 113.07 -1.02 (-0.89%)
On watch
Volume:
212,354
Avg Vol (1m):
481,736
Market Cap $:
5.02 Bil
Enterprise Value $:
4.26 Bil
P/E (TTM):
11.63
P/B:
1.63
Financial Strength | 7/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 1.95 | ||
| Equity-to-Asset | 0.73 | ||
| Debt-to-Equity | 0.26 | ||
| Debt-to-EBITDA | 1.28 | ||
| Interest Coverage | 15.61 | ||
| Piotroski F-Score | 7 | ||
| Altman Z-Score | 5.14 | ||
| Beneish M-Score | -2.62 | ||
| WACC vs ROIC | |||
Profitability Rank | 8/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 38.72 | ||
| Net Margin % | 30.04 | ||
| ROE % | 15.24 | ||
| ROA % | 10.71 | ||
| ROC (Joel Greenblatt) % | 68.08 | ||
| 3-Year Revenue Growth Rate | -1.1 |
Valuation Rank | 7/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 11.63 | ||
| Forward PE Ratio | 9.36 | ||
| PE Ratio without NRI | 11.63 | ||
| Price-to-Owner-Earnings | 11.41 | ||
| PB Ratio | 1.63 | ||
| PS Ratio | 3.45 | ||
| Price-to-Free-Cash-Flow | 8.35 | ||
| Price-to-Operating-Cash-Flow | 7.49 | ||
| EV-to-EBIT | 7.39 | ||
| EV-to-EBITDA | 6.79 | ||
| EV-to-Revenue | 2.95 | ||
| Shiller PE Ratio | 14.46 | ||
| Current Ratio | 7.43 | ||
| Quick Ratio | 7.08 | ||
| Days Inventory | 306.26 | ||
| Days Sales Outstanding | 43.87 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.7 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 1.71 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 0.83 | ||
| Price-to-Median-PS-Value | 0.92 | ||
| Price-to-Peter-Lynch-Fair-Value | 0.34 | ||
| Price-to-Graham-Number | 0.94 | ||
| Earnings Yield (Greenblatt) % | 13.53 | ||
| Forward Rate of Return (Yacktman) % | 28.29 |